There are about 355 million people suffering from arthritis in the world, and an average of 1 in 6 people in Asia suffers from arthritis. According to relevant statistics from the Orthopedic Branch of the Chinese Medical Association, there are about 122 million arthritis patients in China, among which osteoarthritis accounts for more than 70% of bone and joint diseases.
About 51% of people over the age of 50 suffer from osteoarthritis, and the proportions of women and men over the age of 65 are 90% and 80%, respectively. Studies have confirmed that nutrient supplementation is one of the effective ways to improve joint health, osteoporosis and muscle loss. It can be seen that whether it is improving arthritis or general health, it means a huge incremental market. Glucosamine, collagen, curcumin, and other important ingredients for maintaining joints have received a lot of attention. Among them, glucosamine bears the brunt.
According to the statistics of the authoritative department of the Southern Institute, the market size of the national glucosamine industry (raw material medicine with capsules) has exceeded 6 billion yuan in 2020, and continues to grow at a rate of about 20% per year. From the data released by ReportLinker, it can be seen that the global bone and joint supplement market will reach US$14.7 billion in 2027. Since 2003, about 320 health foods (glucosamine) have been approved and registered, accounting for about 55.2% of all bone density health foods in China.
In the first half of 2021, the scale of the Tmall glucosamine market exceeded 600 million yuan, a year-on-year increase of more than 40%. China’s leading supplement company, BY-HEALTH, best-selling products are Glucosamine Chondroitin Calcium Tablets and protein powder, which will continue to exceed 1 billion yuan in 2021. (Source: rse-health)
Visit HPA-China’s Information Hub, CLICK HERE